IP Library Granted Patent US 12,263,119
Granted Patent B2
US 12,263,119 · App. 17/259,017 · Granted Apr 1, 2025

Opthalmic dispensing device

Inventor: Jakub Zarczuk (Karolkowa, PL)
Assignee: Zaklady Farmaceutyczne Polpharma S.A.
A61F9/0008A61K9/0048A61K31/5377A61K31/5575A61K47/02A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,119
App. No.
17/259,017
Granted
Apr 1, 2025
Kind
B2
Abstract

The present invention is directed to a dispensing device comprising: an ophthalmic liquid composition comprising a prostaglandin analogue; a container with the ophthalmic liquid composition comprising a prostaglandin analogue packaged therein; a dropper; and a gasket, wherein the gasket is made of a polymer substantially free of ethylene-vinyl acetate or plasticiser. The present invention further refers to a dropper and a gasket for the dispensing device and to a preservative-free aqueous ophthalmic composition of latanoprost.

Claims (44)

1. A dispensing device comprising:

an ophthalmic liquid composition comprising a prostaglandin analogue;

a container with the ophthalmic liquid composition comprising the prostaglandin analogue packaged therein;

a dropper; and

a gasket,

wherein the gasket is substantially free of plasticizer and the gasket comprises a polymer selected from the group consisting of polyethylene, polypropylene, polytetrafluoroethylene and mixtures thereof.

2. The dispensing device according to claim 1 wherein the prostaglandin analogue is a prostaglandin F2α analogue.

3. The dispensing device according to claim 1 , wherein the ophthalmic liquid composition comprises a prostaglandin analogue in a concentration up to 100 micrograms/millilitre.

4. The dispensing device according to claim 1 , wherein the ophthalmic liquid composition is an aqueous solution, an emulsion or a suspension.

5. The dispensing device according to claim 1 , wherein the ophthalmic liquid composition further comprises a surfactant.

6. The dispensing device according to claim 1 , wherein the ophthalmic liquid composition is preservative-free.

7. The dispensing device according to claim 1 , wherein the ophthalmic liquid composition comprises at least one further pharmaceutically active substance.

8. The dispensing device according to claim 1 , wherein the polymer consists of polyethylene.

9. The dispensing device according to claim 1 , wherein the container comprises a polymer selected from the group consisting of polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), polyvinyl chloride, acrylic resins, polystyrene, polymethylmethacrylate, nylon 6 and mixtures thereof.

10. The dispensing device according to claim 1 , wherein the ophthalmic liquid composition is an aqueous solution comprising:

latanoprost in a concentration comprised in the range 0.010-0.100 mg/ml;

polysorbate 80 in a concentration comprised in the range 0.2-1.0 mg/ml;

disodium edetate in a concentration comprised in the range 0.1-0.5 mg/ml;

a tonicity agent in an amount sufficient to adjust the osmolality to a value comprised in the range 250-320 mOsmol/kg;

an ophthalmically acceptable buffering agent;

optionally, a pH adjusting agent to adjust the pH to a value in the range 5.5-6.5; and

water, as solvent.

11. The dispensing device according to claim 10 , wherein the tonicity agent is selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, propylene glycol, glycerol, sorbitol, mannitol and mixtures thereof.

12. The dispensing device according to claim 10 , wherein the buffering agent is selected from acetate, citrate, phosphate, and borate buffers.

13. The dispensing device as defined according to claim 10 , wherein the ophthalmic liquid composition comprises timolol, or a pharmaceutically acceptable salt thereof, as a second active ingredient.

14. A gasket for the dispensing device as defined in claim 1 .

15. The gasket according to claim 14 , wherein said polymer consists of polyethylene.

16. A dropper for the dispensing device according to claim 1 , comprising the gasket as defined in claim 14 .

17. A preservative-free aqueous ophthalmic solution comprising:

latanoprost in a concentration comprised in the range 0.010-0.100 mg/ml;

optionally, timolol or a pharmaceutically acceptable salt thereof, in a concentration comprised in the range 1-10 mg/ml;

polysorbate 80 in a concentration comprised in the range 0.2-1.0 mg/ml;

disodium edetate in a concentration comprised in the range 0.1-0.5 mg/ml;

a tonicity agent in an amount sufficient to adjust the osmolality to a value comprised in the range 250-320 mOsmol/kg;

an ophthalmically-acceptable buffering agent;

optionally, a pH adjusting agent, to adjust the pH to a value in the range 5.5-6.5; and

water, as solvent.

18. A dispensing device comprising:

an ophthalmic liquid composition comprising a prostaglandin analogue;

a container with the ophthalmic liquid composition comprising the prostaglandin analogue packaged therein;

a dropper; and

a gasket,

wherein the gasket comprises 2% or less of plasticizer and the gasket comprises a polymer selected from the group consisting of polyethylene, polypropylene, polytetrafluoroethylene and mixtures thereof.

19. The dispensing device according to claim 18 , wherein the gasket consists of polyethylene.

Assignments (2)
MERGER Recorded Jul 11, 2024
From: WARSZAWSKIE ZAKLADY FARMACEUTYCZNE POLFA SA
To: ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Reel/Frame 068283/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2021
From: ZARCZUK, JAKUB
To: WARSZAWSKIE ZAKLADY FARMACEUTYCZNE POLFA SA
Reel/Frame 055134/0110 →
Priority Claims (1)
EP 18460042 · Jul 9, 2018 · regional
Continuity (1)
Related Publication 20210282965A1 · Sep 16, 2021
References Cited (10)
US 2877810A · Zackheim · 1959 [cited by examiner]
US 20010002012A1 · Yeaton · 2001 [cited by examiner]
US 20050287325A1 · Baket et al. · 2005 [cited by applicant]
US 20070297990A1 · Shah · 2007 [cited by examiner]
US 20100216877A1 · Kshirsagar · 2010 [cited by examiner]
US 20160082194A1 · Furukawa · 2016 [cited by examiner]
EP 2193795 · 2010 [cited by applicant]
WO WO2009145356 · 2009 [cited by applicant]
WO WO2017182138A1 · 2017 [cited by examiner]
International Search Report for PCT/PL2019/000052, issued Oct. 28, 2019. [cited by applicant]